Morgan Stanley Names NetEase Its Top Pick Ahead of Ananta’s 2027 Global Launch
The $163 price target sits about 35% above the latest close.
Already have an account? Sign in.
The $163 price target sits about 35% above the latest close.
Leerink cut Bristol Myers and raised Zentalis. Barclays lowered uniQure. Cantor upgraded Rezolute. New Buy calls on Ovid, Maravai, and Regenxbio.
Morgan Stanley keeps a bullish view on SpaceX, citing growth and a cheaper way into the space and intelligence economy ahead of Flight 15.
Option Care Health is in advanced talks on a joint bid from McKesson and CD&R valuing it at more than $5 billion, including debt.